Products for Research Use Only

Pimonidazole

CAT: 0804-HY-105129A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-105129A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Pimonidazole is a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in tumor[1]. Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after reduction of its nitro group, it can be used for qualitative and quantitative assessment of tumor hypoxia [2].
CAS Number
70132-50-2
UNSPSC
12352005
Hazard Statement
H302
Target
Others
Type
Reference compound
Related Pathways
Others
Applications
Neuroscience-Neuromodulation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pimonidazole.html
Purity
99.32
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 1 mg/mL (ultrasonic)
Smiles
OC(CN1C=CN=C1[N+]([O-])=O)CN2CCCCC2
Molecular Formula
C11H18N4O3
Molecular Weight
254.29
Precautions
H302
References & Citations
[1]Varia MA, et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol. 1998 Nov;71 (2) :270-7.|[2]Masaki Y, et al. Imaging Mass Spectrometry Revealed the Accumulation Characteristics of the 2-Nitroimidazole-Based Agent "Pimonidazole" in Hypoxia. PLoS One. 2016 Aug 31;11 (8) :e0161639.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Citation 01
Exp Neurol. 2025 Aug 27:115447.|Mater Today Bio. 2025 Sep 30;35:102370.|Sci Rep. 2023 Apr 21;13 (1) :6528.|Theranostics. 2022 Apr 4;12 (7) :3196-3216.|Asian J Pharm Sci. 2023 May;18 (3) :100798.|Exp Eye Res. 2025 Oct:259:110557.|J Colloid Interface Sci. 2024 May:661:908-922.|J Colloid Interface Sci. 2025 Aug 28;702 (Pt 1) :138870.